Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPGM | P07738 | 2/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24348498 | 0.88 | BPGM (0.57) | BPGMPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL24348492 | 0.87 | BPGM (0.53) | BPGMPIK3CAPIK3CDPIK3CGPIK3CB | |
| SCHEMBL24348493 | 0.87 | BPGM (0.54) | BPGMPIK3CAPIK3CDMEN1KMT2A | |
| SCHEMBL24349250 | 0.85 | BPGM (0.55) | BPGMPIK3CAPIK3CDMEN1KMT2A | |
| SCHEMBL24348501 | 0.85 | BPGM (0.63) | BPGMPIK3CAPIK3CDMEN1KMT2A | |
| SCHEMBL24349009 | 0.83 | BPGM (0.60) | BPGMPIK3CAPIK3CDMEN1KMT2A | |
| SCHEMBL24348036 | 0.83 | BPGM (0.61) | BPGMPIK3CAPIK3CDMEN1KMT2A | |
| SCHEMBL24348548 | 0.83 | BPGM (0.77) | BPGMPIK3CAPIK3CDMEN1KMT2A | |
| SCHEMBL24348051 | 0.82 | BPGM (0.55) | BPGMPIK3CAPIK3CD | |
| SCHEMBL24348037 | 0.82 | BPGM (0.60) | BPGMPIK3CAPIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| WO-2022056449-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348454-A1 | COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, HBG1 | BPGM 1/4885PIK3CA 568/4885PIK3CD 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.